×
  • Category
  • Type
  • Advanced

Recommandations provisoires concernant l’utilisation du vaccin ChAdOx1-S [‎recombinant]‎ contre la COVID-19 (‎vaccin anti-COVID-19 d’AstraZeneca AZD1222 Vaxzevria™, SII COVISHIELD™)‎

Recommandations provisoires pour l’utilisation du vaccin anti-COVID-19 inactivé BIBP développé par China National Biotec Group (‎CNBG)‎, Sinopharm

Recommandations provisoires pour l’utilisation du vaccin anti-COVID-19 BBV152 COVAXIN® de Bharat Biotech

TechNet Conference 2015: Designing the supply chain (1 of 2)

Outil de calcul des coûts d'introduction et de déploiement des vaccins contre la COVID-19 (outil CVIC)

Vaccin ChAdOx1-S [recombinant] contre la COVID-19

Vaccin contre la COVID-19 (cellule Vero), inactivé, CoronaVac

Bénéfices sanitaires de la vaccination contre le rotavirus chez les enfants en Palestine: Résultats de l’analyse d’impact d’un vaccin

Background document on the Novavax (NVX-CoV2373) vaccine against COVID-19

Recommandations provisoires pour l’utilisation du vaccin Novavax NVX-CoV2373 contre la COVID-19

COVAXIN® (BBV152) – Inactivated, COVID-19 vaccine

Annexes to the interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19 - update 15 March 2022

Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19 - update 15 March 2022

Background document on the Bharat Biotech BBV152 COVAXIN® (COVID-19) vaccine

Group B Streptococcus vaccine: full value of vaccine assessment. Financial analysis

Full Value of Vaccine Assessment: Group B Streptococcus Vaccine - Policy and Implementation Issues

Full Value of Vaccine Assessment: Group B Streptococcus Vaccine Executive Summary

Group B Streptococcus Vaccine: full value vaccine assessment

The Health Benefits of Rotavirus Immunization for Children in Palestine: Results of a Vaccine Impact Analysis

Moderna COVID-19 Vaccine - Vaccine Preparation and Administration Summary